Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01204723 · ClinicalTrials.gov registry record · Phase 1
Medications Development for the Treatment of Cannabis Related Disorders
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT01204723: Completed Phase 1 study, sponsored by University of Virginia.
NCT01204723 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 63 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01204723, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
Primary Outcome
Subjective experience of withdrawal symptoms for cannabis, tobacco, and both (eg: Irritability, Sleep difficulty, Chills, Nervousness)
Interventions
- DRUG Placebo Aprepitant
- DRUG Active Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
What the finished NCT01204723 record still lists
NCT01204723 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo Aprepitant is the first listed.
NCT01204723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01204723 about?
NCT01204723 is a clinical study titled "Medications Development for the Treatment of Cannabis Related Disorders". The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
What is the current status of trial NCT01204723?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2009-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01204723?
The interventions under investigation include: Placebo Aprepitant (DRUG), Active Aprepitant (DRUG).
Who is sponsoring clinical trial NCT01204723?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01204723's enrollment target sits among peer trials
63 820th of 2000 higher than 1,177 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia